Spectrofluorimetric determination of dl-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine in pharmaceuticals and chitosan solution

A spectrofluorimetric method for the determination of d,l-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine, fluoxetine (F), in pharmaceuticals was evaluated in the 50.0-500.0 μg ml− 1 range. Linearity, sensibility, quantification and detection limit, and precision values are satisfactor...

Full description

Saved in:
Bibliographic Details
Published in:International journal of food sciences and nutrition 2012-02, Vol.63 (1), p.125-128
Main Author: Rodrigues, Máira Regina
Format: Article
Language:English
Subjects:
anti-depressive drug
chitosan
Chitosan - chemistry
Chitosan - pharmacology
Diet, Reducing
Dietary Fats - metabolism
Drug Interactions
fluoxetine
Fluoxetine - chemistry
Fluoxetine - isolation & purification
Hypolipidemic Agents - chemistry
spectrofluorimetry
Spectrometry, Fluorescence - methods
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A spectrofluorimetric method for the determination of d,l-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine, fluoxetine (F), in pharmaceuticals was evaluated in the 50.0-500.0 μg ml− 1 range. Linearity, sensibility, quantification and detection limit, and precision values are satisfactory. The method does not need pre-treatment and was successfully applied to the determination in pharmaceuticals and chitosan (Ch) solution. Ch has an ability to carry and absorb fat and may eventually be used together with F in slimming diets, and then interactions of Ch-F may occur. This work seeks to study these interactions by monitoring the photophysics of a drug in the presence of Ch. The results warn about the care that must be taken when both compounds are prescribed together.
ISSN:0963-7486
1465-3478
DOI:10.3109/09637486.2011.605348